A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects with, or at Risk for, Manifest Huntington's Disease
Administered By
Awarded By
Contributors
- Scott, Burton Lasater Principal Investigator
Start/End
- August 6, 2020 - December 31, 2020